Molecular Structure, Processing, and Tissue Distribution of Matrilin-4*

Andreas R. Klatt, D. Patric Nitsche, Birgit Kobbe, Marcus MachtDagger , Mats Paulsson, and Raimund Wagener§

From the Institute for Biochemistry and the Dagger  Center for Molecular Medicine Cologne Service Laboratory, Medical Faculty, University of Cologne, Joseph-Stelzmann-Strasse 52, D-50931 Cologne, Germany

Received for publication, January 22, 2001, and in revised form, February 12, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Matrilin-4 is the most recently identified member of the matrilin family of von Willebrand factor A-like domain containing extracellular matrix adapter proteins. Full-length matrilin-4 was expressed in 293-EBNA cells, purified using affinity tags, and subjected to biochemical characterization. The largest oligomeric form of recombinantly expressed full-length matrilin-4 is a trimer as shown by electron microscopy, SDS-polyacrylamide gel electrophoresis, and mass spectrometry. Proteolytically processed matrilin-4 species were also detected. The cleavage occurs in the short linker region between the second von Willebrand factor A-like domain and the coiled-coil domain leading to the release of large fragments and the formation of dimers and monomers of intact subunits still containing a trimeric coiled-coil. In immunoblots of calvaria extracts similar degradation products could be detected, indicating that a related proteolytic processing occurs in vivo. Matrilin-4 was first observed at day 7.5 post-coitum in mouse embryos. Affinity-purified antibodies detect a broad expression in dense and loose connective tissue, bone, cartilage, central and peripheral nervous systems and in association with basement membranes. In the matrix formed by cultured primary embryonic fibroblasts, matrilin-4 is found in a filamentous network connecting individual cells.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The matrilins are a novel family of oligomeric extracellular proteins containing von Willebrand factor A (vWFA)1-like domains (1). In mouse, four matrilins exist with matrilin-1, previously referred to as cartilage matrix protein, being the prototype member. The expression of matrilin-1 and -3 is restricted to skeletal tissues, whereas the matrilin-2 and -4 have a broad tissue distribution. It has been suggested that matrilins act as adapter molecules connecting other proteins and proteoglycans in the extracellular matrix (2).

Mouse matrilin-4 has the modular structure typical for matrilins and consists of two vWFA-like domains connected by four epidermal growth factor (EGF)-like domains and a C-terminal alpha -helical coiled-coil domain predicted to mediate oligomerization (3). In addition, a unique splice variant, which does not contain the N-terminal vWFA-like domain, was identified in mouse (3). Matrilin-4, like matrilin-1, lacks the stretch of frequently positively charged amino acids found in other matrilins between the signal peptide cleavage site and the vWFA-like domain at the N-terminal end of the mature protein. The mouse matrilin-4 precursor consists of 624 amino acid residues, and after cleavage of the 21-amino acid signal peptide a mature protein with a predicted minimal mass of 66.4 kDa is formed (3). Human matrilin-4 is highly homologous to the mouse protein with an overall identity of 91% and a maximum identity of 97% in the second vWFA-like domain. Due to a mutation in the splice donor site of the third intron of the human gene, the exon, which corresponds to that specifying the first EGF-like domain in mouse, is not expressed in man. Instead of the four EGF-like domains present in mouse, the human matrilin-4 contains three, two, or one EGF-like domains, probably depending on a differential usage of splice acceptor sites in the exons coding for EGF-like domains (4). When matrilin-4 expression was studied in the mouse by Northern hybridization, mRNA could be detected in lung, sternum, brain, kidney, and heart (3). In the human, matrilin-4 expression was demonstrated by reverse transcriptase-polymerase chain reaction in lung and placenta, as well as in the embryonic kidney cell line 293-EBNA and in WI-26 fibroblasts (4). The broad tissue distribution is reminiscent of that of matrilin-2, and phylogenetic analyses show (1) that matrilin-4 and matrilin-2 descend from a common ancestor, further indicating a close relationship.

We recombinantly expressed the full-length mouse matrilin-4 in a mammalian expression system. The recombinant protein was used for production of a specific antiserum, which allowed immunohistochemical characterization of matrilin-4 expression in the mouse and an analysis of supramolecular assembly forms in the extracellular matrix formed by cultured primary embryonic fibroblasts. The full-length protein was used for structural studies by which the molecular dimensions and oligomeric state of recombinant matrilin-4 could be determined. Structural analysis also revealed a unique, conserved cleavage site used for proteolytic processing of matrilin-4. Extraction of native matrilin-4 from mouse tissues allowed a characterization of the naturally occurring oligomers by SDS-PAGE and Western blotting.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Expression and Purification of Recombinant Matrilin-4-- Murine matrilin-4 cDNA was generated by reverse transcriptase-polymerase chain reaction on total lung RNA. Suitable primers introduced a 5'-terminal SpeI and a 3'-terminal NotI restriction site. The cDNA was inserted into the expression vector pCEP-Pu (5) downstream of the sequence encoding the BM-40 signal peptide. The vector contained either an N-terminal His6-Myc tag downstream of the signal peptide coding sequence and upstream of a 5' NheI site (6) or a C-terminal strepII tag (7) downstream of the NotI site.

The recombinant plasmids were introduced into the human embryonic kidney 293-EBNA cell line (Invitrogen) by transfection with DAC-30TM (Eurogentec). The cells were selected with puromycin (1 µg/ml) and were transferred to serum-free medium for harvesting of the recombinant protein. After filtration and centrifugation (1 h, 10,000 × g), cell culture supernatant containing the N-terminally His6-Myc-tagged matrilin-4 was applied to a nickel-nitrilotriacetic acid column (10 ml, Qiagen). The bound fraction was eluted with 0.25 M imidazole in 2 M urea, 0.3 M NaCl, 50 mM NaH2PO4, pH 8.0. The matrilin-4-containing fractions were diluted with an equal volume 2 M urea, 50 mM Tris-HCl, pH 7.4, and concentrated on a SP HiTrap column (1 ml, Amersham Pharmacia Biotech). Elution was achieved with 1 M NaCl, 2 M urea, 50 mM Tris-HCl, pH 7.4. The cell culture supernatant containing the C-terminally strepII-tagged matrilin-4 was dialyzed against 1 mM EDTA, 0.1 M Tris-HCl, pH 8.0, applied to a streptactin column (3 ml, IBA), and eluted with 2.5 mM desthiobiotin, 1 mM EDTA, 0.1 M Tris-HCl, pH 8.0.

Preparation of Antibodies to Matrilin-4-- The purified, N-terminally His6-Myc-tagged matrilin-4 was used to immunize rabbits. The antiserum obtained was purified by affinity chromatography on a column containing the C-terminally strepII-tagged matrilin-4 coupled to CNBr-activated Sepharose (Amersham Pharmacia Biotech). The specific antibodies were eluted with 0.1 M glycine, pH 2.5, and the eluate was neutralized with M Tris-HCl, pH 8.8.

Tissue Extraction-- Mouse calvaria was extracted for 6 h at 4 °C with 10 volumes (ml/g wet tissue) of 0.1 M NaCl, 50 mM Tris-HCl, pH 7.4, containing 10 mM EDTA and 2 mM N-ethylmaleimide, and mouse brain each consecutively with 5 volumes for 1 min at 4 °C with 0.15 M NaCl, 50 mM Tris-HCl, pH 7.4 (TBS), TBS containing 10 mM EDTA, TBS containing 10 mM EDTA and 4 M urea, and finally 0.1 M Tris-HCl, pH 7.4, containing 10 mM EDTA and 4 M GdnHCl. All extraction buffers contained 2 mM phenylmethylsulfonyl fluoride.

SDS-Polyacrylamide Gel Electrophoresis, Immunoblotting, and Determination of N-terminal Sequences-- SDS-polyacrylamide gel electrophoresis was performed as described by Laemmli (8). For immunoblots the proteins were transferred to nitrocellulose and incubated with the appropriate affinity-purified rabbit antibody diluted in TBS containing 5% low fat milk powder. Bound antibodies were detected by luminescence using peroxidase-conjugated swine anti-rabbit IgG (Dako), 3-aminophthalhydrazide (1.25 mM), p-coumaric acid (225 µM), and 0.01% H2O2. For N-terminal sequencing, proteins were subjected to SDS-polyacrylamide gel electrophoresis and electroblotted to a polyvinylidene difluoride membrane (Immobilon P, Millipore). Protein bands were cut out and their N-terminal amino acid sequences determined in a Applied Biosystems 473A protein sequencer.

In Situ Hybridization-- Tissues from newborn mice were fixed overnight with 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4, at 4 °C, washed overnight with PBS (4 °C), dehydrated, and embedded in paraffin. Sections of 7 µm were cut, mounted on 3-aminopropyltriethoxysilane-treated glass slides, dewaxed in xylene, and rehydrated. After washing in PBS they were digested with 110 milliunits/ml proteinase K, postfixed, and acetylated with 0.25% acetic anhydride. The sections were hybridized overnight at 50 °C with digoxigenin-labeled riboprobes covering the nucleotides 9-704 of the matrilin-4 cDNA (3). After hybridization, the sections were washed in 50% formamide, 2× SSC (0.3 M NaCl containing 0.03 sodium citrate) for 30 min at 50 °C, digested with RNase A, washed once with 2× SSC and twice with 0.2× SSC for 20 min at 50 °C. The immunological detection of the digoxigenin-labeled sections was carried out according to the instructions of the manufacturer (Roche Molecular Biochemicals) with additional use of polyvinyl alcohol in the detection solution (9).

Immunohistochemistry-- Immunohistochemistry was performed on frozen and paraffin-embedded sections of fetal, newborn, and 6-week-old mice. The tissues were prefixed, and the tissues from 6-week-old mice were demineralized with 5% HNO3 overnight at 4 °C. After demineralization the tissues were transferred for 24 h into 5% Na2SO4. Deparaffinization ensued through incubation for 30 min in Rotihistol (Carl Roth GmbH, Karlsruhe, Germany) at 52 °C. After rehydration, the sections were digested with hyaluronidase (500 units/ml PBS, pH 5-6; Sigma) at 37 °C for 30 min followed by proteinase K (5.5 milliunits/ml, in 1 mM EDTA, 10 mM Tris-HCl, pH 7.5; Sigma) at 37 °C for 5-10 min. They were briefly washed with PBS and postfixed with 4% formaldehyde in PBS for 15 min. After three washing steps, the sections were blocked for 1 h with 1% (w/v) bovine serum albumin in TBS and incubated with the affinity-purified matrilin-4 antibodies overnight at 4 °C. The primary antibodies were visualized by consecutive treatment of the sections for 1 h with biotin-SP-conjugated goat anti-rabbit IgG (Dianova) and alkaline phosphatase-conjugated streptavidin (Dianova). All antibodies and the alkaline phosphatase-conjugated streptavidin were diluted in 1% (w/v) bovine serum albumin in TBS, and the slides were developed with fast red TR/naphthol (Sigma). Immunofluorescence and peroxidase staining was performed as described previously (10).

Immunofluorescence Microscopy of Cell Cultures-- Cells were plated onto glass or permanox chamber slides, and after reaching confluence cells were fixed in 4% formaldehyde in PBS. Nonspecific antibody binding was blocked by incubation with 1% (w/v) bovine serum albumin in TBS, and immunolabeling was done by incubation with affinity-purified antibodies to matrilin-4 for 1 h followed by CyTM3-conjugated affinity-pure goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories).

Electron Microscopy-- Negative staining was performed as described previously (11, 12) using non-reduced or reduced samples of C-terminally strepII-tagged matrilin-4 (5-10 µg/ml) stained with 0.75% uranyl formate. Reduction was carried out for 2 h at 20 °C using dithiothreitol (DTT) at concentrations between 0.05 and 10 mM. The reaction was stopped by alkylation with a 3-fold excess of N-ethylmaleimide for 1 h at 20 °C prior to analysis by SDS-PAGE. The sample that showed quantitative conversion to the monomeric form at the lowest DTT concentration was subjected to electron microscopy.

In Gel Digestion of Proteins Separated by SDS-PAGE-- Cut-out gel bands were reduced with 20 mM DTT for 15 min at 37 °C and alkylated with 50 mM iodoacetamide for 15 min at 37 °C in 50 mM ammonium bicarbonate, pH 8.0. The in gel digestion with trypsin or endoprotease Glu-C was carried out overnight at an enzyme concentration of 12.5 ng/µl in 50 mM ammonium bicarbonate buffer, pH 8.0, at 37 °C. Subsequent elution was performed in two steps with 0.1% trifluoroacetic acid/acetonitrile (2:3) for a total of 30 h. The supernatants were pooled and dried in a vacuum centrifuge, and the peptides were dissolved in 5% formic acid.

Mass Spectrometry-- MALDI-TOF mass spectrometry was carried out in a Bruker Reflex III mass spectrometer equipped with a 26-sample SCOUT source and video system, a nitrogen UV laser (lambda max = 337 nm), and a dual channel plate detector (Bruker Daltonik, Bremen, Germany). 1 µl of the sample solution was placed on the target, and 1 µl of a freshly prepared saturated solution of alpha -cyano-4-hydroxycinnamic acid (Aldrich) in acetonitrile/H2O (2:1) with 0.1% trifluoroacetic acid was added. For MALDI-TOF mass spectrometry of intact proteins, sinapinic acid (Aldrich) was used as matrix. When required, the protein was reduced with 0.01 M DTT on the target for 1 h at 37 °C. Cations were detected and analyzed utilizing the high mass detector in the linear mode of a Bruker Reflex III. Calibration was based upon the Mr of recombinant protein A (Repligen) of 44,610.3 and bovine serum albumin dimer (Sigma) of 132,859.0, respectively. Between 50 and 500 single laser shots were summed into an accumulated spectrum. External calibration was carried out using a mixture of six synthetic peptides with molecular masses between 1046 and 2466 Da as well as the protonated dimer of the matrix (379 Da).

Electrospray mass spectrometry was carried out with a Micromass Q-TOF II instrument (Micromass, Manchester, UK). The samples were introduced by nano-ESI. Prior to the analysis the samples were desalted and concentrated using home-built microcolumns consisting of ~2.5 µl of C18-reversed phase material (ODS-AQ, 120 Å, 50 µm; YMC Europe, Schermbeck, Germany) in a gel-loader tip (Biozym, Hessisch-Oldendorf, Germany). The adsorbed peptides were washed with 5% formic acid and subsequently eluted with 3 µl of 5% formic acid/methanol (1:1) directly into a metal-coated nanospray capillary (Protana A/S, Odense, Denmark). Spray voltage was adjusted between 2700 and 3000 V, and block temperature was set to 30 °C. For MS experiments collision energy was set to 12 V, whereas for MS/MS experiments this was raised to a value between 25 and 40 V depending on size and charge state of the precursor ion to obtain optimal fragment ion spectra. Calibration was carried out between m/z 400 and 2500 using 40 mM H3PO4.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Recombinant Expression and Purification of Matrilin-4-- cDNAs encoding the sequence of mature mouse matrilin-4 were cloned into vectors carrying nucleotide sequences coding for either an N-terminal His6-Myc tag (HM4) or a C-terminal strepII tag (M4S). The use of different tags at different positions allowed the evaluation of their potential effects on the properties of the recombinant protein. The constructs were inserted into the pCEP-Pu vector utilizing the secretion signal sequence of BM-40 (5). The recombinant plasmids were introduced into human embryonic kidney 293-EBNA cells and maintained in an episomal form. The secreted matrilin-4 protein constructs were purified from the cell culture medium by affinity chromatography on either a streptavidin or a Ni2+ column. The correct usage of the predicted signal peptide cleavage site was confirmed by N-terminal protein sequencing of the purified recombinant strepII-tagged matrilin-4.

Recombinant Expression of Matrilin-4 Yields Trimers, Dimers, and Monomers-- SDS-PAGE analysis of both the N- and C-terminally tagged proteins showed the presence of trimers, dimers, and monomers, indicating that the tags do not influence the oligomerization (Fig. 1). The His6-Myc tag and the strepII tag contribute 5.5 and 1.3 kDa, respectively, to the mass of each subunit. Without reduction, His6-Myc-tagged matrilin-4 gave three strong bands with apparent molecular weights of 235 (t),2 155 (d + cc), and 66 kDa (m - cc), respectively, and fainter bands at 87 (m +2 cc) and 73 kDa (m). Due to incomplete closure of disulfide bonds minor amounts of uncleaved, free monomers are often seen in matrilin samples. The strepII-tagged matrilin-4 gave strong bands with apparent molecular weights of 210 (t), 150 (d + cc), and 95 kDa (m + 2cc), respectively, and fainter bands at lower molecular weights. The minor bands seen between 65 and 80 kDa most likely represent a mixture of intact monomers with proteolytically processed monomers. The band at 21 kDa is a disulfide-bonded complex of three coiled-coil region fragments (see also Fig. 4). Reduction of the strepII-tagged matrilin-4 yielded a strong band with an apparent molecular mass of 67 kDa (m) (Fig. 1). MALDI-TOF mass spectrometry of non-reduced, strepII-tagged matrilin-4 resulted in three single charged molecule ion peaks at 219 (t), 153 (d + cc), and 87 kDa (m + 2cc) (Fig. 2A). After complete reduction, one single molecule ion peak was detected at 72.9 kDa (m) (Fig. 2C). The theoretical molecular mass of the strepII-tagged, mature matrilin-4 is 67.6 kDa, indicating that 7% of the mass of the recombinantly expressed protein was contributed by post-translational modifications. The larger species observed without prior reduction presumably represent trimers and modified dimers and monomers of the 72.9-kDa subunit.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 1.   SDS-PAGE of recombinant matrilin-4 proteins. N-terminally His6-Myc-tagged (HM4, lane 1) and C-terminally strepII-tagged matrilin-4 (M4S, lanes 2 and 3) were submitted to SDS-PAGE without (lanes 1 and 2) or with (lane 3) prior reduction and stained with silver (lane 1) or Coomassie Brilliant Blue (lanes 2 and 3). Electrophoresis was done on gels containing 4-16% (lane 1) or 4-12% polyacrylamide (lanes 2 and 3). For nomenclature see also Footnote 2 and Fig. 4.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   MALDI-TOF spectra of purified recombinant C-terminally strepII-tagged matrilin-4 under non-reducing (A), partially reducing (B), and fully reducing (C) conditions. B and C, the sample was reduced on target with 10 mM DTT. The inset in C shows the low molecular weight range. M2+ designates the 2-fold positively charged molecule ion species. a.i., arbitrary intensity. m/z, mass per charge. For nomenclature see also Footnote 2 and Fig. 4.

Proteolytic Processing of Recombinant Matrilin-4-- The consistent occurrence of matrilin-4 as a mixture of trimers, dimers, and monomers could be due either to an incomplete assembly of a triple coiled-coil or to cleavage of subunits close to the assembly domain, after formation of the trimer, yielding dimeric and monomeric fragments. Direct SDS-PAGE and Western blot analysis of non-purified culture media from 293-EBNA cells transfected with N- and C-terminally tagged matrilin-4 (Fig. 3) provided an indication of a C-terminal processing of matrilin-4. Bands that correspond to intact trimers as well as dimers and monomers with one and two additional coiled-coil strands, respectively, were observed (Fig. 3, lanes 1 and 2). Also truncated monomers lacking the coiled-coil domain of the N-terminally His6-Myc-tagged and C-terminally strepII-tagged matrilin-4 could be detected (Figs. 3 and 4). Furthermore, the C-terminal processing was confirmed by Western blot analysis of reduced samples from cell culture supernatant of 293-EBNA cells expressing N-terminally His6-Myc-tagged matrilin-4 (Fig. 3, lanes 3 and 4). Both the unprocessed and the C-terminally processed matrilin-4 subunits were detectable by the antiserum against matrilin-4.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 3.   Immunoblot analysis of recombinant matrilin-4 proteins. Cell culture media of 293-EBNA cells transfected with C-terminally strepII-tagged (M4S, lane 1) or N-terminally His6-Myc-tagged matrilin-4 (HM4, lanes 2-4) were submitted to SDS-PAGE, transferred to nitrocellulose, and developed with either the affinity-purified antiserum against matrilin-4 (lanes 1-3) or an monoclonal antibody against the N-terminal Myc tag (lane 4). Lanes 3 and 4, the samples were reduced prior to electrophoresis. Electrophoresis was done on gels containing 4-15 (lane 1 and 2) or 4-8% (lane 3 and 4) polyacrylamide. For nomenclature see also Footnote 2 and Fig. 4. Note that the band patterns in this immunoblot cannot be directly compared with those in Fig. 1, because in Fig. 1 certain fragments had been enriched in the affinity chromatography step by virtue of carrying either an N- or C-terminal tag, and detection was done by protein staining.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 4.   Proteolytic processing of matrilin-4. Schematic representation of the forms of matrilin-4 identified by mass spectrometry and SDS-PAGE of recombinant proteins. cc, coiled-coil region. The underlined sequence was confirmed by N-terminal Edman degradation, and the strepII tag sequence is given in italics. Bold letters indicate sequences confirmed by ESI Q-TOF.

We used MALDI-TOF mass spectrometry to confirm the C-terminal processing by analysis of the fragments released upon cleavage. Partial reduction of the strepII-tagged matrilin-4 on the target yielded new peaks at 146 (d) and 80 kDa (m + cc) in addition to the 72.9 kDa (m) fully reduced monomer (Fig. 2B). This results from the loss of 7-kDa fragments from the 153-kDa (d + cc) and the 87-kDa (m + 2cc) molecule ions, respectively (Fig. 2A). After complete reduction, in addition to the fully reduced monomer of 72.9 kDa, a molecule ion of 6944.8 Da (cc) was detected (Fig. 2C, inset), presumably resulting from the release of a disulfide-bonded fragment. The mass of this fragment corresponds to the C-terminal end of the recombinant matrilin-4 starting with the amino acid residue Gly572 (3) and lacking the very C-terminal lysine residue, with the theoretical mass of 6943.7 Da (Fig. 4). Matrilin-4 fragments without the coiled-coil domain could not be detected as they do not bind to the streptactin column.

SDS-PAGE of recombinant strepII-tagged matrilin-4 without prior reduction shows a band with an apparent molecular mass of ~21 kDa (3cc) that is lost upon reduction (Fig. 1). Isolation of this band followed by in gel trypsin digestion and MALDI-TOF analysis revealed the presence of a tryptic fragment of a mass of 2552.2 Da corresponding to the sequence Gly572 to Arg594, indicating a cleavage between amino acid residues Glu571 and Gly572 in the region between the second vWFA-like domain and the coiled-coil domain (Fig. 4). Under reducing conditions a 7-kDa (cc) fragment of strepII-tagged matrilin-4 was isolated by SDS-PAGE. Subsequent in gel digestion with trypsin and endoprotease Glu-C followed by ESI Q-TOF mass spectrometry yielded two sequences, 572GIGATE and AAAWSHPQFE, originating from the N-terminal end and the C-terminal strepII tag of the 7-kDa (cc) fragment, respectively (Fig. 4), supporting that the fragment results from a proteolytic cleavage between the second vWFA-like domain and the two cysteine residues stabilizing the coiled-coil. In addition, the localization of the cleavage site between residues Glu571 and Gly572 was unequivocally confirmed by Edman sequencing of the 21-kDa (3cc) band (Fig. 1) which gave 572GIG(A/H)TELRS (Fig. 4). A cleavage at this point releases a matrilin-4 subunit, less its coiled-coil domain, which remains disulfide-bonded to the assembly domains from the other matrilin-4 chains (Fig. 4).

Electron Microscopy-- The purified strepII-tagged full-length matrilin-4 was submitted to electron microscopy after negative staining with uranyl formate (Fig. 5). The protein particles were heterogeneous in size, and a closer examination of single particles revealed that all species from monomer to trimer were present in the sample, in agreement with the results from SDS-PAGE and MALDI-TOF analysis. At high magnification it was seen that in oligomers all subunits are joined at a single point in a manner reminiscent of the bouquet-like structure known from other matrilins (2, 10, 11). This indicates assembly of the oligomers via the C-terminal coiled-coil domain. A compact structure was seen at the center of the particles, representing the C-terminal, globular vWFA-like domains. These are connected to the extending N-terminal vWFA-like domains (diameter 5 ± 1 nm) by a well resolved stalk made up from the four EGF-like repeats. The center-to-center distance between the vWFA-domains is 14 ± 2 nm. After mild reduction with 5 mM DTT, the monomers released show two globular units, representing vWFA-like domains, connected by the flexible rod of EGF-like repeats (results not shown). Such reduced monomers have a shape similar to subunits found in non-reduced samples with the same center-to-center distance between the globular domains.


View larger version (121K):
[in this window]
[in a new window]
 
Fig. 5.   Electron microscopy of negatively stained recombinant strepII-tagged matrilin-4. The overview (A) and the panels of selected particles (B-D) demonstrate the heterogeneity in subunit number. The bar corresponds to 100 nm in the overview (A) and to 25 nm in the panels of selected particles (B-D).

Matrilin-4 Is Immunologically Distinct from Other Matrilins-- Purified, N-terminally His6-Myc-tagged matrilin-4 was used for the immunization of a rabbit. The resulting antiserum was affinity-purified by adsorption to a column of CNBr-Sepharose to which strepII-tagged matrilin-4 has been coupled. By this procedure antibodies specific for matrilin-4 were obtained that lacked reactivity to the tags. The specificity was verified by SDS-PAGE of culture media from 293-EBNA cells expressing N- and C-terminally tagged matrilin-4 followed by immunoblotting (Fig. 3). It was further shown that these antibodies do not cross-react with other matrilins in immunoblots (Fig. 6A).


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 6.   SDS-PAGE and immunoblot of tissue extracts. Proteins extracted from calvaria (A and B) or brain (C) of newborn mice and recombinant C-terminally strepII-tagged matrilin-4 (B) were separated on 4-8% polyacrylamide gels without prior reduction, transferred to nitrocellulose, and detected with specific antisera. A, antisera to each of the matrilins were used (M1-4). C, brain of a newborn mouse (C) was sequentially extracted with TBS alone (TBS), TBS with 10 mM EDTA (EDTA), TBS with 4 M urea and 10 mM EDTA (Urea), and TBS with 4 M GdnHCl (GuHCl). (Cv, calvaria; M4S, C-terminally, strepII-tagged matrilin-4.) For nomenclature see also Footnote 2 and Fig. 4. The dashed lines connect bands in A and B representing the same components.

Characterization of Matrilin-4 Extracted from Mouse Tissues-- To study the structure of tissue-derived matrilin-4 and to identify similarities or differences to the recombinantly expressed protein, extracts from several murine tissues were analyzed by non-reducing SDS-PAGE and immunoblotting using the affinity-purified antiserum against matrilin-4. Among these tissues, sternum, calvaria, cerebellum, medulla oblongata, spinal cord, cortex, lung, and muscle were positive, whereas heart, testis, colon, and adrenal gland were negative for matrilin-4 (results not shown). In an extract of murine calvaria, a major band with an apparent molecular mass of 200 kDa, representing the trimeric form of matrilin-4, was detected (Fig. 6A, lane 4). Two additional bands were detected at 180 and 170 kDa that may represent degradation products or alternative assembly forms of matrilin-4. A direct comparison after longer exposure of a calvaria extract with recombinant matrilin-4 shows bands in the tissue extract presumably corresponding to the 150-kDa dimer (d + cc), the 95-kDa monomer (m + 2cc), and the 67-kDa cleaved monomer (m - cc) bands of recombinant strepII-tagged matrilin-4 (Fig. 3 and Fig. 6B), indicating that the cleavage characterized for the recombinant matrilin-4 expressed in 293-EBNA cells may occur also in vivo. The nitrocellulose blots obtained with calvaria extract were also incubated with affinity-purified antisera raised against matrilin-1, -2, and -3 (Fig. 6A). All matrilins are expressed in mouse calvaria, but hetero-oligomers formed between matrilin-4 and another matrilin could not be identified on the basis of co-migration of immunoreactive bands. Furthermore, the band patterns obtained for matrilin-1 and -3 (Fig. 6A, lanes 1 and 3) indicate that these mainly occur as homo-oligomers in murine calvaria, even though heterotetramers of these matrilins have been unambiguously demonstrated in bovine cartilage (10, 13). This is in agreement with the recent result that hetero-oligomers formed between matrilin-1 and -3 cannot be detected in mouse epiphyseal and tracheal cartilage (14).

Sequential extraction of mouse brain indicated a differential solubility of the individual oligomeric forms of matrilin-4 (Fig. 6C). All forms could be solubilized in EDTA-containing buffer but not in TBS alone, which indicates a contribution to the anchorage by a divalent cation-dependent mechanism. Denaturation with urea released large additional amounts of trimeric matrilin-4 and the 170-kDa form. Further denaturation with 4 M GdnHCl released only the trimeric form of matrilin-4, indicating that the unprocessed protein is most strongly bound to insoluble tissue elements.

Matrilin-4 Is Deposited in Loose and Dense Connective Tissue, below Epithelia, in Smooth Muscle and in Nervous Tissue-- The tissue distribution of matrilin-4 was studied by immunohistochemistry using affinity-purified antibodies on cryostat and paraffin-embedded sections of embryonic, newborn, and 6-week-old mice. The earliest expression of matrilin-4 was detected by immunofluorescence in the ectoplacental cone at day 7.5 post-coitum (results not shown). At day 10.25 post-coitum matrilin-4 is present in the heart (Fig. 7A), cephalic mesenchymal tissue (Fig. 7B), and somites, while at day 14.5 post-coitum it was found in the primordial skeleton and cranial bones, in the larynx, and in the lung (Fig. 7C). A similar characterization of the expression of matrilin-1, -2, and -3 in mouse embryos has been performed earlier (15).


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 7.   Immunohistochemical detection of matrilin-4 in fetal mouse tissues. Matrilin-4 was detected in sections of mouse embryos from days 10.25 and 14.25 post-coitum. At day 10.25 post-coitum, matrilin-4 was found in the trabeculae of the heart (A) as well as in the cephalic mesenchymal tissue (mt) (ne, neuroepithelium). At day 14.25 post-coitum (C), matrilin-4 is present in the cartilage primordia of the vertebra (vb), sternum (sn), and the hip (hp), in the anlage of cranial bones such as the bones of the nasal cavity (nc), Meckels cartilage (mc), and basisphenoid bone (bb). Furthermore, it could be detected in the thyroid (td) and tracheal (tc) cartilages and around the terminal bronchioli of the lung (lg). Bar, 1.8 (C), 0.08 mm (A and B).

After birth, the protein is abundant in dense connective tissue, including perichondrium, periosteum, tendon, and ligaments (Fig. 8A). Furthermore, matrilin-4 is highly expressed in cartilage (Fig. 8, A-D and I). In the knee of a newborn mouse (Fig. 8A), matrilin-4 is present at the joint surface, as well as in the resting, proliferating, and hypertrophic cartilage, while at 6 weeks (Fig. 8B) it was found in the epiphyseal growth plate and in the cartilage remnants in the metaphysis but not in the articular cartilage. In loose connective tissue, it is present under stratified squamous epithelia (Fig. 9B'), in the papillary layer of the dermis (Fig. 8E), in the smooth muscle layer of the intestine (Fig. 8F), and in the interalveolar walls of the lung (Fig. 8G). In the esophagus (Fig. 9B') and the dermis (Fig. 8E) matrilin-4 was found associated with the basement membrane. In the eye (Fig. 8H) it is expressed in the cornea and sclera and strongly in the limbus. Furthermore, matrilin-4 is present in the fibrous skeleton and in the valves of the heart (Fig. 8, D and I), in the primordium of the incisors (Fig. 8C), and at lower levels in the adrenal gland (not shown).


View larger version (121K):
[in this window]
[in a new window]
 
Fig. 8.   Tissue distribution of matrilin-4. Immunohistochemistry was performed on paraffin-embedded (A-E and G-J) or frozen (F) tissue from newborn (A, C---E, and G-I) or 6-week-old (B and J) mice, or from a day 15.5 post-coitum mouse embryo (F), which were demineralized if needed (B). Tissues were incubated with an affinity-purified antiserum against matrilin-4 followed by either biotin-SP-conjugated goat anti-mouse IgG and alkaline phosphatase-conjugated streptavidin (A---D and G-J), or by CyTM-3-conjugated goat anti-rabbit IgG (E and F). In the knee of a newborn mouse (A), matrilin-4 was highly expressed throughout the cartilage including the developing articular surface (as), the perichondrium (pc), periost (po), and ligaments (lm). In the epiphyseal cartilage primordium of the distal femur (fm) and proximal tibia (tb), matrilin-4 was found in the zone of resting (rt), proliferating (pl), and hypertrophic (ht) cartilage. In the knee of a 6-week-old mouse (B), a strong signal could be detected in the epiphyseal growth plate (gp) and in the calcified area (ca) of newly synthesized bone. In a transverse section through the head (C), matrilin-4 was found in the developing occipital bones (ob), bones of the nasal cavity (nc), the nasal septum (ns), the inner and outer mesenchymal layer of hair follicles (hf), and in the primordium of the upper incisors (ic). In the thorax (D), matrilin-4 is present in the trachea (tc), in costal cartilage (cc), in vertebral bodies (vb) and their transverse processes (tp), in the manubrium sternum (ms) and processus xiphoideus (px), in the clavicula (cv), and in the spinal cord (sc) (os, esophagus). In the skin (E), matrilin-4 was found in the fibrillar network of the papillary layer (pl) and associated with the dermal-epidermal basement membrane (bm). Further signals were detected in the smooth muscle (sm) layer of the intestine (F) (lm, lumen) and in the interalveolar walls (iw) of the lung (G). In the eye (H), matrilin-4 is present in the cornea (cn) and sclera (sr) and strongly in the limbus (lb). In the heart, matrilin-4 was found in the fibrous skeleton (arrow, D) and in the valves (vv, I). Matrilin-4 is broadly distributed in the brain (C and J), where it is present in the neocortex (nc), striatum (st), pallidum (pd), thalamus (tm), hippocampus (hc), cerebellum (cb), pons (ps), and medulla oblongata (mo). Bar, 2.8 (C), 2.3 (J), 1.6 (D), 0.7 (H), 0.6 (I), 0.5 (A and B), 0.3 (G) and 0.075 mm (E and F).


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 9.   Comparison of the distribution of matrilin-4 protein and mRNA. Antisense riboprobes labeled with digoxigenin were hybridized to paraffin-embedded sections of a humeroradial joint of a newborn mouse (A) and to sections of esophagus (B) and cerebellum (C) of an adult mouse. Parallel sections were immunolabeled with affinity-purified matrilin-4 antibody (A', B', and C'). In the joint (jt), hybridization is strongest at the developing articular surface corresponding to strong signals of the immunofluorescence (hm, humerus; rd, radius). In the esophagus, mRNA is present in the epithelial cells (ec), and the protein is associated with the underlying basement membrane. Hybridization of the cerebellum showed high transcription levels in the Purkinje cells (pk), whereas the protein was detected most strongly in the white matter (wm) and in the granular layer (gl). Bar, 0.7 (C), 0.4 (B), and 0.3 mm (A).

Matrilin-4 is also widely distributed in the central nervous system and in peripheral nerves. In the adult brain (Fig. 8J), matrilin-4 was observed in the neocortex, striatum, pallidum, thalamus, cerebellum, pons, medulla oblongata, and in the choroid plexus (results not shown). It was further present in the spinal cord (Fig. 8D) and in the sympathetic ganglion (results not shown).

The Matrilin-4 Gene Is Transcribed in Fibroblasts, Chondroblasts, Osteoblasts, Epithelial, Muscle, and Neuronal Cells-- The cellular origins of matrilin-4 were revealed by in situ hybridization and the results compared with the information on the deposition of the protein derived from immunohistochemistry. In sections through a humeroradial joint (Fig. 9, A and A'), the highest mRNA levels could be detected in the perichondrium and at the joint surface, in good agreement with to the staining pattern obtained by immunohistochemistry. In the esophagus (Fig. 9, B and B'), epithelial cells show clear hybridization signals. Matrilin-4 mRNA was also detected in Purkinje cells in the cerebellum (Fig. 9, C and C'). Skeletal muscle cells and osteoblasts showed a weak but significant level of gene expression (results not shown).

Matrilin-4 Forms an Extracellular Filamentous Network in Cell Culture-- In order to study the extracellular assembly forms of matrilin-4, mouse primary embryonic fibroblasts were cultured in the presence of ascorbate and analyzed by immunofluorescence. The filamentous network (Fig. 10) seen was reminiscent of that detected by antibodies to matrilin-1 (16), -2 (11), and -3 (10) in other cell culture systems.


View larger version (122K):
[in this window]
[in a new window]
 
Fig. 10.   Immunofluorescence microscopy of matrilin-4-containing filaments in the extracellular matrix of primary embryonic mouse fibroblasts. Cells were cultured in the presence of ascorbate. Matrilin-4 was detected with affinity-purified antibodies followed by a CyTM3-conjugated affinity-purified goat anti-rabbit IgG. Bar, 0.14 mm.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Recombinant Matrilin-4 Forms Homotrimers-- SDS-PAGE analysis, MALDI-TOF mass spectrometry, and electron microscopy showed the production of matrilin-4 homotrimers in 293-EBNA cells transfected with matrilin-4 cDNA. In electron microscopy (Fig. 5) the trimeric form shows similarities to the bouquet-like shape observed for other matrilins (2, 10, 11) with a compact center from which stalk-like structures with globular ends extend. Self-interactions of the vWFA-like domains, as proposed to occur between the A1 and A2 domains in matrilin-1 and -2 (2, 11), were not visible.

Zhang and Chen (17) used rules based on the nature of the hydrophobic residues in positions "a" and "d" of the heptad repeat of coiled-coils in GCN4 leucine zipper mutants (18) to predict that based on sequence matrilin-4 would form trimers. Our experimental work shows that this prediction holds true, as is also the case for matrilin-1 and -3 that according to the same rules should form trimers and tetramers, respectively. However, the largest assembly form of matrilin-2 is a tetramer (11) and not a trimer as predicted on the basis of the rules of Harbury et al. (18). The trimers seen in matrilin-2 preparations are, in analogy with matrilin-4, likely to be degradation products. In contrast to the tetrameric assembly form of full-length matrilin-2, the isolated matrilin-2 coiled-coil domain assembles preferentially into a trimer (19). It appears that prediction of the oligomeric state of matrilin coiled-coil domains (17) leaves uncertainties and that experimental analysis is required.

Previous studies showed that the coiled-coil domain of matrilin-1 folds autonomously (20), even though the second vWFA-like domain possibly also plays a role (21). Matrilin-3, which lacks a second vWFA-like domain, and matrilin-2, which carries a unique segment adjacent to the coiled-coil, form tetramers, whereas matrilin-1 and -4 form trimers. In contrast, hetero-oligomers of matrilin-1 and -3 occur as both trimers and tetramers (11, 13, 17). Therefore, the oligomerization may also be influenced by the distance between the second vWFA-like domain and the coiled-coil domain.

Matrilin-4 Dimers and Monomers Are Formed by Cleavage of Trimers-- Supernatants of matrilin-4 transfected 293-EBNA cells contain a complex mixture of different oligomeric forms. Such heterogeneity was also seen for matrilin-2 and -3, both when expressed recombinantly and when extracted from tissues (10, 11, 17), although matrilin-1 appears more homogenous in tissues (Fig. 6) (22). It has been suggested that the heterogeneity could result either from a proteolytic processing (10, 11) or from an imperfect oligomerization (10, 17). Proteolytic degradation products of matrilin-4 could be demonstrated by mass spectrometry, Edman sequencing, and SDS-PAGE analysis. A cleavage site could be identified that is located between the second vWFA-like domain and the coiled-coil domain, leading to the formation of truncated forms that are trimeric with respect to their coiled-coil domains but lack the more N-terminal parts of the subunit. Only dimers and monomers containing the intact trimeric coiled-coil were detected by MALDI-TOF analysis (Fig. 3), which excludes imperfect oligomerization as the cause for heterogeneity. The demonstration of N-terminally truncated but trimeric matrilin-4 directly shows that the oligomerization is achieved by the C-terminal coiled-coil domain. Further studies will be needed to determine when and where the processing occurs in vivo and the nature of the protease involved.

Matrilin-4 Extracted from Tissues Shows a Degradation Pattern Reminiscent of Recombinant Matrilin-4-- The pattern of degradation products present in recombinant matrilin-4 shows similarities to that seen for matrilin-4 extracted from tissues (Fig. 6B), indicating that proteolytic processing occurs also in vivo. The two glutamic acid residues N-terminal to the cleavage site of matrilin-4 are conserved in all matrilins, indicating that this cleavage site may be used also in other matrilins. For matrilin-2 it was shown that the heterogeneous band pattern seen in SDS-PAGE is not due to differential substitution with glycosaminoglycans or N-linked oligosaccharides (11).

Oligomeric forms of matrilins will be multivalent and able to interact with and connect multiple other extracellular matrix molecules. A proteolytic cleavage of one or two subunits would release interaction partners from the supramolecular complex formed and could modulate the overall binding properties of matrilins. This is supported by the fact that the larger forms of matrilin-4 require more strongly denaturing conditions for their extraction from tissues (Fig. 6). Still a proportion of matrilin-4 molecules could be extracted with EDTA-containing buffer alone, indicating a cation-dependent anchorage in the extracellular matrix. A similar behavior has been described for matrilin-1 (2). The vWFA-like domains of matrilins contain the metal ion-dependent adhesion site sequence motif, and the fact that at least some interactions of matrilin-1 and -4 can be stabilized by divalent cations indicates that this motif is indeed functional.

Proteolytic cleavage of extracellular matrix molecules is a common mechanism for the regulation of the matrix architecture during remodeling, and perturbations in the balance of proteolysis and de novo protein synthesis may form a basis for pathological changes in tissue structure and function. Furthermore, degradation products may have a function different from that of the unprocessed protein, e.g. endostatin, a fragment of the NC1 domain of collagen type XVIII, acts as an angiogenesis inhibitor (23). It remains to be investigated if fragments released by degradation of matrilins may have such independent new functions.

Matrilin-4 Is the Most Widespread Member of the Matrilin Family-- Matrilin-4 is present in highest amounts in tissues derived from mesenchymal cells, but additionally in situ hybridization showed transcription in epithelial and neuronal cells, which have developed from endoderm and neuroectoderm, respectively. In contrast to matrilin-2 and matrilin-1 and -3 that have a complementary tissue distribution, matrilin-4 is found in most locations where one of the other matrilins is expressed. Similar to matrilin-2, it is present in a variety of non-skeletal tissues, but in contrast matrilin-4 is broadly expressed in cartilage where the matrilin-2 expression is limited to the hypertrophic zone of the growth plate. Furthermore, matrilin-4 is present in the surface layer of the developing articular cartilage, where no other matrilin has been detected. The partial overlap in the spatial expression of matrilins may allow a functional redundancy that could explain the lack of an overt phenotype seen when the matrilin-1 gene is interrupted (14, 24).

Matrilin-4 Forms an Extended Extracellular Network-- Immunofluorescence microscopy of the matrix formed by cultured primary embryonic fibroblasts shows matrilin-4 in an extended filamentous network. The filaments have a variable thickness, often form branches, and connect cells over a distance of several cell diameters (Fig. 10). Similar results were obtained for matrilin-1 in cultures of chicken chondrocytes, where a more extended collagen-dependent (16, 25) and a pericellular, collagen-independent network was described (16). Matrilin-2 and -3 also form fibrillar networks when expressed by cultured rat aorta smooth muscle (11) or rat chondrosarcoma cells (10), indicating mechanisms of supramolecular assembly common to all matrilins.

The Matrilin Family Consists of Four Members-- Matrilin-4 is in all probability the final member of the matrilin family. No further members have been detected in the sequence data bases including those provided by the human genome project. This is supported by phylogenetic studies showing that each of the four matrilin genes is located in a gene cluster together with members of other tetralog protein families such as the syndecans (26). Each member of the matrilin family has in the meantime been characterized with regard to structure and distribution in embryonal and mature tissues, which allows some conclusions about the overall role of the matrilin family. The widespread distribution of matrilins with at least one family member being present in nearly every tissue and at very different time points of development indicates an important role in the structure and function of an extracellular matrix. A common feature of the matrilins is the ability to participate in the formation of a filamentous network but probably also to bind ligands adjacent to or within those filaments. This is facilitated by the oligomeric structure, which enables the simultaneous interaction with multiple ligands. Ligand binding affinity could be modified by altering cooperativity through proteolytic processing, an event that may not be restricted to matrilin-4. The broad tissue distribution of matrilin-4, which nearly covers the expression domains of all other matrilins, makes it likely that matrilin-4 is the most versatile member of the family. Therefore, our further work will focus on matrilin-4 in the hope that detailed studies of this matrilin will enhance the general understanding of matrilin structure and function.

    ACKNOWLEDGEMENTS

We thank Drs. Ferenc Deák and Neil Smyth for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft Grant WA 1338/2-1 and by Köln Fortune program of the Medical Faculty of the University of Cologne.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Institute for Biochemistry II, Medical Faculty, University of Cologne, Joseph-Stelzmann-Str. 52, D-50931 Cologne, Germany. Tel.: 49-221-478-6990; Fax: 49-221-478-6977; E-mail: Raimund.Wagener@uni-koeln.de.

Published, JBC Papers in Press, February 14, 2001, DOI 10.1074/jbc.M100587200

2 To allow simple identification of protein components on the basis of the results of mass spectrometry (Fig. 2) and protein sequencing (Fig. 4), we introduce a nomenclature where t represents trimer, d represents dimer, and m represents monomer. These designations are followed by a - cc or a + cc. The - cc indicates that the coiled-coil region is absent from the subunit, and + cc shows that the fragment carries additional coiled-coil regions bound by disulfide bonds and derived from other cleaved subunits. The digit before cc refers to the number of these coiled-coil fragments when more than one is carried. For example m + 2cc means a monomer connected by disulfide bonds to two additional coiled-coil region fragments thereby forming a triple coiled-coil alpha -helix. For a schematic depiction of this nomenclature see Fig. 4.

    ABBREVIATIONS

The abbreviations used are: vWFA, von Willebrand factor A; EGF, epidermal growth factor; PAGE, polyacrylamide gel electrophoresis; MALDI-TOF matrix-assisted laser desorption ionization/time-of-flight, ESI Q-TOF, electrospray ionization quadrupole/time-of-flight; DTT, dithiothreitol; PBS, phosphate-buffered saline; MS, mass spectrometry; ESI, electrospray ionization.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Deák, F., Wagener, R., Kiss, I., and Paulsson, M. (1999) Matrix Biol. 18, 55-64[CrossRef][Medline] [Order article via Infotrieve]
2. Hauser, N., and Paulsson, M. (1994) J. Biol. Chem. 269, 25747-25753[Abstract/Free Full Text]
3. Wagener, R., Kobbe, B., and Paulsson, M. (1998) FEBS Lett. 436, 123-127[CrossRef][Medline] [Order article via Infotrieve]
4. Wagener, R., Kobbe, B., and Paulsson, M. (1998) FEBS Lett. 438, 165-170[CrossRef][Medline] [Order article via Infotrieve]
5. Kohfeldt, E., Maurer, P., Vannahme, C., and Timpl, R. (1997) FEBS Lett. 414, 557-561[CrossRef][Medline] [Order article via Infotrieve]
6. Wuttke, M. (2001) Characterization of the Structure and Function of Recombinant and Native Human Bone Sialoprotein. Doctoral dissertation , University of Cologne, Germany
7. Smyth, N., Odenthal, U., Merkl, B., and Paulsson, M. (2000) Methods Mol. Biol. 139, 49-57[Medline] [Order article via Infotrieve]
8. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
9. De Block, M., and Debrouwer, D. (1993) Anal. Biochem. 215, 86-89[CrossRef][Medline] [Order article via Infotrieve]
10. Klatt, A. R., Nitsche, D. P., Kobbe, B., Mörgelin, M., Paulsson, M., and Wagener, R. (2000) J. Biol. Chem. 275, 3999-4006[Abstract/Free Full Text]
11. Piecha, D., Muratoglu, S., Mörgelin, M., Hauser, N., Studer, D., Kiss, I., Paulsson, M., and Deák, F. (1999) J. Biol. Chem. 274, 13353-13361[Abstract/Free Full Text]
12. Engel, J., and Furthmayr, H. (1987) Methods Enzymol. 145, 3-78[Medline] [Order article via Infotrieve]
13. Wu, J. J., and Eyre, D. R. (1998) J. Biol. Chem. 273, 17433-17438[Abstract/Free Full Text]
14. Aszódi, A., Bateman, J. F., Hirsch, E., Baranyi, M., Hunziker, E. B., Hauser, N., Bösze, Z., and Fässler, R. (1999) Mol. Cell. Biol. 19, 7841-7845[Abstract/Free Full Text]
15. Segat, D., Frie, C., Nitsche, P. D., Klatt, A. R., Piecha, D., Korpos, E., Deák, F., Wagener, R., Paulsson, M., and Smyth, N. (2000) Matrix Biol. 19, 649-655[CrossRef][Medline] [Order article via Infotrieve]
16. Chen, Q., Johnson, D. M., Haudenschild, D. R., Tondravi, M. M., and Goetinck, P. F. (1995) Mol. Biol. Cell 6, 1743-1753[Abstract]
17. Zhang, Y., and Chen, Q. (2000) J. Biol. Chem. 275, 32628-32634[Abstract/Free Full Text]
18. Harbury, P. B., Zhang, T., Kim, P. S., and Alber, T. (1993) Science 262, 1401-1407[Medline] [Order article via Infotrieve]
19. Pan, O. H., and Beck, K. (1998) J. Biol. Chem. 273, 14205-14209[Abstract/Free Full Text]
20. Beck, K., Gambee, J. E., Bohan, C. A., and Bächinger, H. P. (1996) J. Mol. Biol. 256, 909-923[CrossRef][Medline] [Order article via Infotrieve]
21. Chen, Q., Zhang, Y., Johnson, D. M., and Goetinck, P. F. (1999) Mol. Biol. Cell 10, 2149-2162[Abstract/Free Full Text]
22. Paulsson, M., and Heinegård, D. (1981) Biochem. J. 197, 367-375[Medline] [Order article via Infotrieve]
23. Zätterström, U. K., Felbor, U., Fukai, N., and Olsen, B. R. (2000) Cell Struct. Funct. 25, 97-101[CrossRef][Medline] [Order article via Infotrieve]
24. Huang, X., Birk, D. E., and Goetinck, P. F. (1999) Dev. Dyn. 216, 434-441[CrossRef][Medline] [Order article via Infotrieve]
25. Winterbottom, N., Tondravi, M. M., Harrington, T. L., Klier, F. G., Vertel, B. M., and Goetinck, P. F. (1992) Dev. Dyn. 193, 266-276[Medline] [Order article via Infotrieve]
26. Gibson, T. J., and Spring, J. (2000) Biochem. Soc. Trans. 28, 259-264[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.